A Johns Hopkins University-initiated clinical trial is starting to enroll an estimated 900 relapsing-remitting multiple sclerosis (RRMS) patients to assess the benefits of switching therapies to prevent ... Read more
Akili Interactive announced it has received a $55 million in financing to develop a digital platform to possibly treat people with cognitive impairment associated with diseases like multiple ... Read more
Novartis’ investigational oral treatment siponimod (BAF312) reduces the risk of disability progression in patients with secondary progressive multiple sclerosis (SPMS), a new analysis of Phase 3 trial ... Read more
Infection with the common Epstein-Barr virus (EBV) may increase the risk of developing multiple sclerosis (MS), a new report from the Cincinnati Children’s Hospital Medical Center says. Besides ... Read more
Treatment with Ocrevus (ocrelizumab) shows sustained efficacy and an ability to improve cognition in patients with relapsing multiple sclerosis (MS), according to data being presented by Genentech, ... Read more
The United States and Australia have issued patents on Sonde Health‘s voice-analysis technology for diagnosing and monitoring multiple sclerosis and other diseases that affect speech. Sonde, which has ... Read more
A new company called Pipeline Therapeutics will focus on developing next-generation therapies for regenerating the key nerve-protection process that is damaged in multiple sclerosis. Roche, Inception ... Read more
Topline results of an exploratory Phase 2 clinical trial revealed that Flex Pharma‘s treatment candidate FLX-787 improves muscle cramps, spasms and muscle stiffness in patients with multiple ... Read more
MMJ Bio Science has become the first company to obtain a Canadian license to produce medical cannabis, with the initial authorization covering products for multiple sclerosis and Huntington’s disease. The Health ... Read more
Biogen and AbbVie have voluntarily withdrawn global marketing authorizations for their relapsing multiple sclerosis therapy Zinbryta (daclizumab) because of serious side effects that include brain inflammation. The Europe Medicine Agency, which ... Read more
Registered patients in Canada can now purchase CanniMed Topical Cream, a product with medical cannabis oil designed to provide fast-acting relief for patients with multiple sclerosis (MS) ... Read more
Understanding multiple sclerosis (MS) progression will be the focus of the Multiple Sclerosis Association of America’s (MSAA) campaign for MS Awareness Month 2018. March has been recognized as MS ... Read more
Celgene’s Ozanimod reduces relapsing multiple sclerosis patients’ relapses, brain lesions, and brain volume loss, a Phase 3 clinical trial shows.
The company presented the results of the SUNBEAM ... Read more
Brabio (glatiramer acetate injection), the first generic alternative to Copaxone for relapsing multiple sclerosis (MS) patients, was recently launched in the U.K. at an equivalent higher dose, ... Read more
A combination therapy of low-dose methylprednisolone and interferon (IFN)-beta-secreting stem cells is effective in a mouse model of multiple sclerosis (MS), a new Korean study suggests.
The ... Read more
Tailored molecular treatments for specific disabilities may be a breakthrough for multiple sclerosis (MS) patients, finds a new study by researchers at University of California-Los Angeles (UCLA). ... Read more
Non-invasive brain stimulation reduces fatigue in multiple sclerosis patients, concludes a study by researchers at New York University.
Fatigue is one the most disabling symptoms of MS, affecting ... Read more
Gilenya decreased relapses in children and adolescents with multiple sclerosis in the phase 3 PARADIGMS trial, according to the therapy’s developer, Novartis.
The Swiss company will present ... Read more
Pin It on Pinterest